|
|
|
| Untersuchte Arbeit: Seite: 17, Zeilen: 8-17 |
Quelle: Wright 2005 Seite(n): 58, Zeilen: r.col: 6-19 |
|---|---|
| SP-B is essential for the ability of surfactant to reduce surface tension (Nogee, 2004), and SP-C has recently been shown to bind lipopolysaccharide (LPS) (Augosto et al., 2002; Augosto et al., 2003). In the absence of surfactant, surface tension is extremely high at end expiration and tends to collapse the lung. This makes breathing difficult to the extent that respiration is frequently impossible without ventilatory support and surfactant replacement. A deficiency of surfactant – which can result in “Respiratory-Distress Syndrome (RDS)” – occurs when infants are born prematurely, before their surfactant biosynthetic machinery has matured. Treatment of these premature infants with exogenous surfactant replacement reduces mortality and morbidity, because of this disease (Wright, 2005).
Augusto LA, Li J, Synguelakis M, Johansson J, Chaby R. Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide. J Biol Chem. 2002 Jun 28; 277 (26): 23484-92. Epub 2002 Apr 29. Augusto LA, Synguelakis M, Johansson J, Pedron T, Girard R, Chaby R. Interaction of pulmonary surfactant protein C with CD14 and lipopolysaccharide. Infect Immun. 2003 Jan; 71 (1): 61-7. Nogee LM. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu Rev Physiol. 2004; 66: 601-23. Review. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005 Jan; 5 (1): 58-68. Review. |
SP-B is essential for the ability of surfactant to reduce surface tension3, and SP-C has recently been shown to bind lipopolysaccharide (LPS)4,5. In the absence of surfactant, surface tension is extremely high at end expiration and tends to collapse the lung. This makes breathing difficult to the extent that respiration is frequently impossible without ventilatory support and surfactant replacement. A deficiency of surfactant — which can result in RESPIRATORY-DISTRESS SYNDROME — occurs when infants are born prematurely, before their surfactant biosynthetic machinery has matured. Treatment of these babies with exogenous surfactant replacement (BOX 1) reduces mortality and morbidity due to this disease.
3. Nogee, L. M. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu. Rev. Physiol. 66, 601–623 (2004). 4. Augusto, L. A. et al. Interaction of pulmonary surfactant protein C with CD14 and lipopolysaccharide. Infect. Immun. 71, 61–67 (2003). 5. Augusto, L. A., Li, J., Synguelakis, M., Johansson, J. & Chaby, R. Structural basis for interactions between lung surfactant protein C and bacterial lipopolysaccharide. J. Biol. Chem. 277, 23484–23492 (2002). |
The source is given, but the extent of the copied text is not clear to the reader. Neither is it clear that the copy is almost literal. Also three references to the literature are taken from the source. |
|